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SildenaﬁlWe investigated whether atorvastatin has beneﬁcial hemodynamic effects during acute pulmonary thrombo-
embolism (APT) and whether sildenaﬁl improves these effects. We studied the involvement of oxidative
stress, matrix metalloproteinases (MMPs), and neutrophil activation. APT was induced with autologous
blood clots (500 mg/kg) in anesthetized male lambs pretreated with atorvastatin (10 mg/kg/day, subcutane-
ously; 1 week) or vehicle (dimethyl sulfoxide 10% subcutaneously). Sildenaﬁl (0.7 mg/kg intravenously) or
saline infusions were performed 60 min after APT induction. Non-embolized control animals received saline.
APT signiﬁcantly increased pulmonary vascular resistance index (PVRI) and mean pulmonary artery pressure
(MPAP) by approximately 310% and 258% respectively. While atorvastatin pretreatment attenuated these in-
creases (~150% and 153%, respectively; Pb0.05), its combination with sildenaﬁl was associated with lower
increases in PVRI and MPAP (~32% and 36%, respectively). Gelatin zymography showed increased MMP-9
and MMP-2 levels in the bronchoalveolar lavage, and increased MMP-9 levels in plasma from embolized an-
imals. Atorvastatin pretreatment attenuated bronchoalveolar lavage MMP-2 increases. The combination of
drugs blunted the MMPs increases in bronchoalveolar lavage and plasma (Pb0.05). Neutrophils accumulated
in bronchoalveolar lavage after APT, and atorvastatin pretreatment combined with sildenaﬁl (but not atorva-
statin alone) attenuated this effect (Pb0.05). APT increased lung lipid peroxidation and total protein concen-
trations in bronchoalveolar lavage, thus indicating oxidative stress and alveolar–capillary barrier damage,
respectively. Both increases were attenuated by atorvastatin pretreatment alone or combined with sildenaﬁl
(Pb0.05). We conclude that pretreatment with atorvastatin protects against the pulmonary hypertension as-
sociated with APT and that sildenaﬁl improves this response. These ﬁndings may reﬂect antioxidant effects
and inhibited neutrophils/MMPs activation.ology, Faculty of Medicine of
tes, 3900, 14049-900 Ribeirao
633 2301.
ahoo.com (J.E. Tanus-Santos).
vier OA license.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Acute pulmonary thromboembolism is a relatively common com-
plication of deep venous thrombosis (Tapson, 2008). While the me-
chanical obstruction of pulmonary vessels is the major cause of
increased right ventricle overload after acute pulmonary thromboem-
bolism, active vasoconstriction of the pulmonary bed aggravates the
increases in pulmonary vascular resistance and may lead to acute
right heart failure, circulatory shock, and death (Elliott, 1992). There-
fore, the use of selective pulmonary vasodilators has been valued as
an important approach to counteract the pulmonary vasoconstriction
during acute pulmonary thromboembolism (Smulders, 2000; 2001).Sildenaﬁl, a speciﬁc type 5 phosphodiesterase inhibitor, causes pref-
erential pulmonary vasodilation by activating the nitric oxide-cyclic
guanosine monophosphate pathway and attenuates the hemodynamic
derangements associated with experimental (Dias-Junior and Tanus-
Santos, 2006; Dias-Junior et al., 2005a, 2005b, 2010 Souza-Silva et al.,
2005) and clinical (Bonatti et al., 2010a, 2010b; Ganiere et al., 2006;
Lewis et al., 2004) acute pulmonary thromboembolism. Importantly,
in the last few years some authors have suggested that combining sta-
tins with sildenaﬁl augments the protective effects exerted by statins
alone (Kuang et al., 2010; Rosanio et al., 2006; Zhao et al., 2009). In
fact, statins have cholesterol-independent effects including enhanced
nitric oxide bioavailability, and therefore sildenaﬁl may have
positive pharmacodynamic interactions with statins (Castro et al.,
2004). However, although recent studies have examined the beneﬁcial
effects exerted by statins in animal models of pulmonary hypertension,
which may be improved by combining statins with sildenaﬁl (Kuang et
al., 2010; Zhao et al., 2009), no previous study has examined whether
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acute pulmonary thromboembolism.
In the present study, we hypothesized that sildenaﬁl could improve
the protective effects exerted by atorvastatin against the hemodynamic
derangements associated with acute pulmonary thromboembolism.
In addition, increased matrix metalloproteinases (MMPs) activities
contribute to the increases in pulmonary vascular resistance (Fortuna
et al., 2007; Souza-Costa et al., 2005, 2007) and right ventricle cardio-
myocyte injury (Neto-Neves et al., 2011) associated with acute pulmo-
nary thromboembolism, and both sildenaﬁl (Dias-Junior et al., 2009)
and atorvastatin (Souza-Costa et al., 2007) blunted MMPs release during
acute pulmonary thromboembolism. Therefore, we examined whether
sildenaﬁl improves the effects of atorvastatin on acute pulmonary
thromboembolism-induced increases inMMP levels and oxidative stress,
which is a major factor controlling MMPs activation (Castro et al., 2009).2. Materials and methods
2.1. Animal model and hemodynamic measurements
The study compliedwith the international guidelines of the European
Community for the use of experimental animal andwas approved by the
institutional ethics committee.
Twenty two male mixed-bred lambs (17.8±2.9 kg) were ran-
domly assigned to pretreatment with atorvastatin (10 mg/kg/day)
(Ozturk and Uma, 2010; Rosanio et al., 2006) subcutaneously or vehicle
(2 ml of dimethyl sulfoxide 10% in saline) for 1 week. After this pre-
treatment, the animals were anesthetized with ketamine (15 mg/kg, i.
m.), xylazine (0.1 mg/kg, i.m.) and relaxed with pancuronium
(0.1 mg/kg), tracheally intubated, and their lungs were mechanically
ventilated with room air using a volume-cycled respirator (C. F. Palmer,
London, UK). The tidal volume was set at 15 ml/kg and the respiratory
rate was adjusted to maintain a baseline physiologic arterial carbon
dioxide tension. Anesthesia was maintained with intramuscular injec-
tions of ketamine (5–7 mg/kg) and midazolam (0.5–1 mg/kg) every
30 min.
Saline-ﬁlled catheters were placed into the left femoral artery and
right femoral vein for mean systemic arterial pressure monitoring via
a pressure transducer and ﬂuid administration, respectively. A 7.5F
balloon-tipped Swan-Ganz thermodilution catheter was placed into
the pulmonary artery via the left femoral vein. The catheter was con-
nected to pressure transducers to allow the monitoring of mean pul-
monary artery pressure, central venous pressure, and pulmonary
artery occlusion pressure. Thermodilution cardiac output measure-
ments were determined in triplicate by injecting 3 ml of saline and
the results recorded (DX2010Monitor, Dixtal do Brasil, Manaus, Brazil).
The heart rate was measured using a surface electrocardiogram
(lead I).
A venous blood sample (5 ml/kg) was collected and allowed to
clot for at least 60 min, then cut into 2- to 3-mm cubes. In the present
study, acute pulmonary thromboembolism was induced by infusing
the autologous clots (250 mg/kg) for 5–10 min via a large-bore can-
nula placed in the right atrium. This model of acute pulmonary
thromboembolism is very similar to that previously reported (Dias-
Junior et al., 2006; Neto-Neves et al., 2011). After at least 20 min of
stabilization, baseline hemodynamics were measured (BL time
point). The animals were randomly assigned to one of four experi-
mental groups as follows: (1) a group of shamoperated, non-embolized
animals (n=4), that were pretreated with vehicle and received saline
infusions; (2) Emb group (n=6) of animals that were pretreated with
vehicle, embolized, and then received saline infusions; (3) Ator+Emb
group (n=6) of animals that were pretreated with atorvastatin
(10 mg/kg/day), embolized, and then received saline infusions; (4)
Ator+Emb+Sild group (n=6) of animals that were pretreated with
atorvastatin (10 mg/kg/day), embolized, and then received an infusionof sildenaﬁl (0.7 mg/kg over 30 min) (Krebs et al., 2007; Rosanio et al.,
2006).
Hemodynamic evaluation was performed 15, 30, 45, and 60 min
after the acute pulmonary thromboembolism induction (E15, E30,
E45 and E60 time points, respectively) and then 15, 30, 60, and
90 min after sildenaﬁl or saline infusions (S15, S30, S60, and S90
time points respectively). The cardiac index, systemic vascular resis-
tance index, and pulmonary vascular resistance index were calculated
by standard formula.
Arterial blood samples were collected at BL and S90 time points and
plasma samples were stored at−70 °C until used for gelatin zymogra-
phy ofMMP-2 andMMP-9 as described below. The animalswere eutha-
nized with an overdose of anesthetics, and the bronchoalveolar lavage
was performed. Lung samples were collected, snap frozen, and stored
at−70 °C until used to assess lipid peroxidation levels.
2.2. Bronchoalveolar lavage
Bronchoalveolar lavage was performed six times by instilling
20 ml of phosphate-buffered saline containing 1 mM EDTA. Total
cell counts in the bronchoalveolar lavage were performed with a
cell counter (Coulter AC T series analyzer; Coulter Corp., Miami,
USA), and differential cell counts were carried out on cytocentrifuge
slides (Cytospin 3; Shandon Southern Products, Astmoore, UK)
stained by the May–Grünwald–Giemsa (Rosenfeld) method (Souza-
Costa et al., 2007). The total protein concentration in the bronchoal-
veolar lavage supernatant was measured (as an index of alveolar–
capillary barrier damage) by the Bradford assay using bovine serum
albumin as the standard, and the results were expressed as μg/μl. An-
other aliquot was stored at−70 °C until used for gelatin zymography
of MMP-2 and MMP-9 as described below.
2.3. Assessment of MMP-2 and MMP-9 in plasma and in bronchoalveolar
lavage samples by SDS-polyacrylamide gel electrophoresis (PAGE) gelatin
zymography
Gelatin zymography of MMP-9 and MMP-2 of plasma and bronch-
oalveolar lavage samples was performed as previously described
(Dias-Junior et al., 2009; Neto-Neves et al., 2011). Brieﬂy, plasma and
bronchoalveolar lavage samples were subjected to electrophoresis on
7% SDS-PAGE co-polymerized with gelatin (1%) as the substrate (at
150 V for approximately 4 h). After electrophoresis was complete, the
gels were incubated for 1 h at room temperature in a 2% Triton X-100
solution, and incubated at 37 °C for 16 h in Tris–HCl buffer, pH 7.4, con-
taining 10 mmol/l CaCl2. The gels were stained with 0.05% Coomassie
Brilliant Blue G-250 for 3 h, and then destained with 30% methanol
and 10% acetic acid. Gelatinolytic activities were detected as unstained
bands against the background of Coomassie blue-stained gelatin. The
gelatinolytic activities were normalized with regard to an internal stan-
dard (bovine fetal serum) to allow intergel analysis and comparison.
The forms of MMP-2 and MMP-9 were identiﬁed as bands at 72 and
92 kDa, respectively (Dias-Junior et al., 2009; Neto-Neves et al., 2011).
2.4. Assessment of lipid peroxidation levels in the lung
Lung lipid peroxidation levels were determined by measuring thio-
barbituric acid reactive substances using a spectrophotometric method
as previously described (Ohkawa et al., 1979). The lipid peroxidation
levels were expressed in terms of malondialdehyde (nmol/g).
2.5. Statistical analysis
The results are expressed asmeans±S.E.M. Two-way (treatments×
time) analysis of variance for repeated measures and Bonferroni post-
test were used to compare hemodynamic parameters. Biochemical pa-
rameters were compared between groups by one-way analysis of
556 E.M. Neto-Neves et al. / European Journal of Pharmacology 670 (2011) 554–560variance followed by the Dunnett multiple comparisons test. A proba-
bility valueb0.05 was considered the minimum level of statistical
signiﬁcance.Fig. 2. Systemic vascular resistance index (SVRI) and mean arterial pressure (MAP) at
baseline (BL), 15 min, 30 min, 45 min, and 60 min (E15, E45, and E60, respectively)
after acute pulmonary thromboembolism (APT) or saline infusion, and 15 min,
30 min, 60 min, and 90 min (S15, S30, S60, and S90, respectively) after sildenaﬁl or sa-
line infusion in the Sham (n=4), Emb (n=6), Ator+Emb (n=6) and Ator+Emb+3. Results
3.1. Hemodynamic responses
We found no signiﬁcant hemodynamic changes in the Sham group
(Figs. 1–3). Acute pulmonary thromboembolism increased the pul-
monary vascular resistance index by approximately 310% and the
mean pulmonary arterial pressure by 258% (Pb0.05; Fig. 1). While
acute pulmonary thromboembolism had no signiﬁcant effects on
the mean arterial pressure and cardiac index, it increased the heart
rate by approximately 70% (Pb0.05; Fig. 3). The systemic vascular re-
sistance index increased slightly in the Emb group compared with the
Sham group at the S90 time point (Pb0.05, Fig. 2).
Pretreatment with atorvastatin attenuated the increases in the
pulmonary vascular resistance index and in the mean pulmonary ar-
terial pressure (by 150% and 153%, respectively; both Pb0.05; Fig. 1)
associated with acute pulmonary thromboembolism, without signiﬁ-
cant effects on the mean arterial pressure and systemic vascular resis-
tance index (Fig. 2). Interestingly, the infusion of sildenaﬁl decreased
the mean pulmonary arterial pressure and the pulmonary vascular re-
sistance index (by 32% and 36%, respectively; both Pb0.05; Fig. 1) in
the Ator+Emb+Sil group at the S15, S30, S60 and S90 time points.
However, the administration of sildenaﬁl decreased the mean arterial
pressure and the systemic vascular resistance index at S30 and S90
time points (Pb0.05, Fig. 2).Fig. 1. Pulmonary vascular resistance index (PVRI) and mean pulmonary arterial pres-
sure (MPAP) at baseline (BL), 15 min, 30 min, 45 min, and 60 min (E15, E45, and E60,
respectively) after acute pulmonary thromboembolism (APT) or saline infusion, and
15 min, 30 min, 60 min, and 90 min (S15, S30, S60, and S90, respectively) after silden-
aﬁl or saline infusion in the Sham (n=4), Emb (n=6), Ator+Emb (n=6) and Ator+
Emb+Sild (n=6) groups. Values are the mean±S.E.M. ⁎ Pb0.05 for Emb group versus
Sham, Ator+Emb and Ator+Emb+Sild groups. # Pb0.05 for Ator+Emb group versus
Ator+Emb+Sild group at S15, S30, S60 and S90 time points.
Sild (n=6) groups. Values are the mean±S.E.M. # Pb0.05 for Ator+Emb group versus
Ator+Emb+Sild group. ⁎⁎ Pb0.05 for Emb group versus Sham group.
Fig. 3. Cardiac index (CI) and heart rate (HR) at baseline (BL), 15 min, 30 min, 45 min,
and 60 min (E15, E45, and E60, respectively) after acute pulmonary thromboembolism
(APT) or saline infusion, and 15 min, 30 min, 60 min, and 90 min (S15, S30, S60, and
S90, respectively) after sildenaﬁl or saline infusion in the Sham (n=4), Emb (n=6),
Ator+Emb (n=6) and Ator+Emb+Sild (n=6) groups. Values are the mean±
S.E.M. ⁎Pb0.05 for Emb group versus Sham group.
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We examined the effects of pretreatment with atorvastatin and
sildenaﬁl infusion on the increases in MMPs associated with acute
pulmonary thromboembolism. Fig. 4A shows a representative zymo-
gram of plasma samples. Acute pulmonary thromboembolism in-
creased plasma MMP-9 levels by N250% (Pb0.05). While no
signiﬁcant changes were found in the Ator+Emb group, animals in
Ator+Emb+Sild group presented minor, not statistically signiﬁcant
increases in plasmaMMP-9 levels after acute pulmonary thromboem-
bolism (PN0.05, Fig. 4A and B). We found no signiﬁcant increases in
plasma MMP-2 levels (Fig. 4C).
In parallelwith these results,we found that acute pulmonary throm-
boembolismcausedmajor increases inMMP-9 andMMP-2 levels in BAL
samples (Pb0.05), which were blunted in the Ator+Emb+Sild group
(Pb0.05, Fig. 5A–D). Atorvastatin pretreatment was associated with
signiﬁcant reductions in MMP-2 levels (Pb0.05, Fig. 5D), but not
with signiﬁcant reductions in MMP-9 levels (Fig. 5B).
3.3. Neutrophils and protein concentrations in bronchoalveolar lavage
samples
Fig. 6 shows that the increases in MMPs levels after acute pulmo-
nary thromboembolism were associated with major increases in the
number of neutrophils and in protein concentrations (which reﬂect
alveolar–capillary barrier damage) measured in the bronchoalveolar
lavage from embolized animals (Pb0.05, Fig. 6A and B, respectively).
While atorvastatin pretreatment alone did not signiﬁcantly reduce
the numbers of neutrophils in the bronchoalveolar lavage, the num-
ber of neutrophils was signiﬁcantly lower in the Ator+Emb+Sild
group compared with the Emb group (Pb0.05, Fig. 6A). Moreover,
lower protein concentrations were found in the Ator+Emb andFig. 4. Representative sodium dodecyl sulfate-polyacrylamide gel electrophoresis gelatin zym
72 kDa corresponding to matrix metalloproteinase-9 and matrix metalloproteinases-2 respe
dard (bovine fetal serum) to allow intergel analysis and comparison. Percentage of baseline
Ator+Emb (n=6) and Ator+Emb+Sild (n=6) groups. Values are the mean±S.E.M. ST
metalloproteinase-9 ⁎Pb0.05 for Emb group versus Sham and Ator+Emb+Sild groups.in the Ator+Emb+Sild groups compared with the Emb group
(Pb0.05, Fig. 6B).
3.4. Lipid peroxidation levels in the lung
We measured thiobarbituric acid reactive substances concentra-
tions in the lungs from animals to assess oxidative stress. As expected,
acute pulmonary thromboembolism was associated with increased
oxidative stress (128% higher thiobarbituric acid reactive substances
levels; Pb0.05; Fig. 7). Both atorvastatin pretreatment alone or com-
bined with sildenaﬁl attenuated the increases in lipid peroxidation
associated with acute pulmonary thromboembolism (Pb0.05; Fig. 7).
4. Discussion
This is the ﬁrst study to demonstrate that pretreatmentwith atorva-
statin attenuates the pulmonary hypertension associated with acute
pulmonary thromboembolism in a whole animal model. More impor-
tantly, we showed for the ﬁrst time that sildenaﬁl improves the beneﬁ-
cial hemodynamic effects exerted by atorvastatin during acute
pulmonary thromboembolism. These protective effects were associated
with reduced lung lipid peroxidation, plasmaMMP-9 levels, bronchoal-
veolar lavage MMPs levels, and neutrophils/protein leakage into the
bronchoalveolar lavage after acute pulmonary thromboembolism. Our
ﬁndings suggest that atorvastatin+sildenaﬁl is an interesting combina-
tion of drugs that could be used in the therapy of acute pulmonary
thromboembolism.
An important mechanism that may explain how sildenaﬁl im-
proves the beneﬁcial hemodynamic effects exerted by atorvastatin
is that this statin may have increased the sensitivity of vascular tis-
sues to sildenaﬁl as a result of increased vascular NO bioavailability
(Castro et al., 2004). In fact, statins upregulate endogenous NOogram of plasma samples at baseline and S90 time point showing the bands of 92 and
ctively (Panel A). Each band detected was normalized with regard to an internal stan-
(BL) MMP-9 (Panel B) and MMP-2 (Panel C) levels in the Sham (n=4), Emb (n=6),
D: internal standard. BL: baseline MMP-2: matrix metalloproteinase-2 MMP-9: matrix
Fig. 5. Representatives sodium dodecyl sulfate-polyacrylamide gel electrophoresis gelatin zymograms of bronchoalveolar lavage samples showing the bands of 92 and 72 kDa cor-
responding to matrix metalloproteinase-9 and matrix metalloproteinase-2 respectively (Panels A and C respectively). Percentage of MMP-9 (Panel B) and MMP-2 (Panel D) levels
compared with those found in the Sham animals. Sham group (n=4), Emb group (n=6), Ator+Emb group (n=6) and Ator+Emb+Sild group (n=6). Values are the mean±S.
E.M. MMP-2: matrix metalloproteinase-2 MMP-9: matrix metalloproteinase-9 # Pb0.05 for Emb group versus Sham and Ator+Emb+Sild groups (Panel B). ⁎ Pb0.05 for Emb group
versus Sham, Ator+Emb and Ator+Emb+Sild groups (Panel D).
Fig. 6. Number of neutrophils (Panel A) and protein concentrations (Panel B) in
bronchoalveolar lavage samples from animals in Sham group (n=4), Emb group
(n=6), Ator+Emb group (n=6) and Ator+Emb+Sild group (n=6). Values are
the mean±S.E.M. BAL: bronchoalveolar lavage # Pb0.05 for Emb group versus Sham
and Ator+Emb+Sild groups (Panel A). ⁎ Pb0.05 for Emb group versus Sham, Ator+
Emb and Ator+Emb+Sild groups (Panel B).
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induced increases in cyclic guanosine monophosphate levels can be
potentiated by increased nitric oxide levels after pretreatment
with atorvastatin.
The increases in bronchoalveolar lavage MMP-2 and MMP-9, and in
plasma MMP-9 levels that we found after acute pulmonary thrombo-
embolism are supported by previous studies, and suggest a role for
MMPs in the pathophysiology of acute pulmonary thromboembolism
(Dias-Junior et al., 2009; Souza-Costa et al., 2005, 2007). Atorvastatin
or the combination of atorvastatin and sildenaﬁl prevented the in-
creases in MMPs after acute pulmonary thromboembolism, as previ-
ously shown in animal models of acute pulmonary thromboembolism
(Dias-Junior et al., 2005a; Souza-Costa et al., 2007). The attenuation
of MMPs activities after acute pulmonary thromboembolism may
explain, at least in part, the beneﬁcial hemodynamic effects ofFig. 7. Thiobarbituric acid reactive substances (TBARS) concentrations expressed in
terms of malondialdehyde (MDA) concentrations in lung samples from animals in
the Sham (n=4), Emb (n=6), Ator+Emb (n=6) and Ator+Emb+Sild (n=6)
groups. Values are the mean±S.E.M. ⁎ Pb0.05 for Emb group versus Sham, Ator+
Emb and Ator+Emb+Sild groups.
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doxycycline (a non selective MMPs inhibitor) was tested in animal
models of acute pulmonary thromboembolism (Fortuna et al.,
2007; Neto-Neves et al., 2011; Palei et al., 2005). In fact, increased
MMP activities may promote vasoconstriction, especially during
acute pulmonary thromboembolism, as previously discussed (Fortuna
et al., 2007; Neto-Neves et al., 2011; Palei et al., 2005). Moreover, our
ﬁndings are in line with previous studies showing that statins, com-
bined with sildenaﬁl or not, attenuated the pulmonary hypertension
in animal models of lung disease, at least in part, because lower MMP-
9 levels were found (Kuang et al., 2010; Lee et al., 2005; Souza-Costa
et al., 2007).
Acute pulmonary thromboembolism induces acute inﬁltration of
inﬂammatory cells into the pulmonary artery wall (Eagleton et al.,
2002), right ventricle (Neto-Neves et al., 2011; Zagorski et al., 2007)
and bronchoalveolar lavage (Souza-Costa et al., 2007; Zagorski et al.,
2003). In fact, increased number of neutrophils, lymphocytes, and
protein concentrations was found in the bronchoalveolar lavage
after pulmonary embolism (Nakos et al., 1998). Therefore, the in-
creasedMMPs levels in the bronchoalveolar lavage may reﬂect activa-
tion of neutrophils, which release large amounts of pre-stored
proteinases includingMMP-9 (Grommes and Soehnlein, 2011). Consis-
tent with these ﬁndings, our results clearly indicate that acute pulmo-
nary thromboembolism causes alveolar–capillary barrier damage. The
minor increases in the number of neutrophils in the bronchoalveolar
lavage that we found in animals treated with atorvastatin combined
with sildenaﬁl suggest that this combination inhibits neutrophil migra-
tion, thus partially protecting against increased proteolytic activity by
MMP-9.
The increases in MMP-9 levels after acute pulmonary thromboem-
bolism and the protective effects by the drugs tested in the present
study may have important implications. Acute pulmonary thrombo-
embolism increases the expression of chemokines (Zagorski et al.,
2003), and MMP-9 regulates the levels of some cytokines and chemo-
kines. For example, MMP-9 activates pro-interleukin-1β into active
interleukin-1β and may also potentiate interleukin-8 activity, thus
promoting a positive feedback between interleukin-8 and MMP-9
(Opdenakker et al., 2001). In this respect, increased interleukin-1β
levels were shown in experimental acute pulmonary thromboembo-
lism (Sun et al., 2011). Although we have not measured the levels
of these mediators in the present study, it is highly probable that
MMP-9 downregulation by the drugs used in the present study, espe-
cially atorvastatin, may have indirectly attenuated neutrophil chemo-
taxis and inhibited the release of proinﬂammatory factors, as
previously shown (Sun et al., 2011).
Injured pulmonary vasculature and activated neutrophils are impor-
tant sources of reactive oxygen and nitrogen species which exacerbate
lung injury (Grommes and Soehnlein, 2011). Indeed, increased oxida-
tive stress has been reported in clinical (Muhl et al., 2006) and experi-
mental acute pulmonary thromboembolism (Dias-Junior et al., 2005a;
Souza-Costa et al., 2005). Supporting this idea, we found increased
lung lipid peroxidation after acute pulmonary thromboembolism. Im-
portantly, atorvastatin pretreatment alone or its combination with sil-
denaﬁl attenuated acute pulmonary thromboembolism-induced
oxidative stress, thus conﬁrming previous ﬁndings (Dias-Junior et
al., 2005a, 2009; Souza-Costa et al., 2005). The antioxidant effect
that we found may have prevented MMPs activation and its conse-
quences discussed above. This is because reactive oxygen species, es-
pecially peroxynitrite, activate MMPs by non-proteolytic mechanisms
(Chow et al., 2007; Schulz, 2007), and attenuation of acute pulmo-
nary thromboembolism-induced oxidative stress by atorvastatin and
sildenaﬁl is another mechanism that may explain how these drugs
may have blunted MMPs activation after acute pulmonary
thromboembolism.
Our study has some limitations that should be taken into consider-
ation. Firstly, we studied the protective effects exerted by atorvastatin,and not therapeutic effects of this drug after acute pulmonary throm-
boembolism. It would be interesting to study statins as a rescue treat-
ment. Secondly, we have not included a group of animals treated only
with sildenaﬁl. However, the hypothesis being tested here was that
sildenaﬁl could improve the beneﬁcial hemodynamic effects exerted
by statins, which has been tested by comparing the effects of sildenaﬁl
(or vehicle) in animals previously treated with atorvastatin. More-
over, the evidence supporting beneﬁcial effects of sildenaﬁl in acute
pulmonary thromboembolism is very strong, and many experimental
studies (Dias-Junior and Tanus-Santos, 2006; Dias-Junior et al., 2005a,
2005b, 2010; Souza-Silva et al., 2005) have consistently shown that sil-
denaﬁl is a very promising drug to be used in the therapy of acute pul-
monary thromboembolism, as suggested by clinical reports (Bonatti et
al., 2010a, 2010b; Ganiere et al., 2006; Lewis et al., 2004).
In conclusion, our study shows that pretreatment with atorvastat-
in protects against the pulmonary hypertension associated with acute
pulmonary thromboembolism and that sildenaﬁl improves this re-
sponse. These ﬁndings may reﬂect antioxidant effects and inhibited
neutrophils/MMPs activation. Clinical studies should be carried out
to validate the beneﬁcial effects exerted by this combination of
drugs during acute pulmonary thromboembolism.
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